Video

Immunotherapy revolutionizes frontline treatment in advanced RCC

Author(s):

Urology Times staff

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Michael E. Hurwitz, MD, PhD, an associate professor of Internal Medicine at the Yale Cancer Center, discusses how immune checkpoint inhibitor–based combination have dramatically altered the frontline treatment paradigm for patients with advanced renal cell carcinoma.

      Related Videos
      Rebecca A. Campbell, MD, answers a question during a Zoom video interview
      Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
      Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
      Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
      Study data point to gender disparities in oncology research citations
      Study data point to gender disparities in oncology research citations
      Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
      Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
      Betty Wang, MD, discusses studies from the 2025 EAU meeting
      Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
      Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
      Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
      Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
      Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
      Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
      Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
      David Braun, MD, on phase 2 trial of an individualized neoantigen therapy for RCC
      David Braun, MD, on phase 2 trial of an individualized neoantigen therapy for RCC
      Fed Ghali, MD, on clinical outcomes in plasmacytoid urothelial carcinoma
      Fed Ghali, MD, on clinical outcomes in plasmacytoid urothelial carcinoma
      Related Content
      Subcutaneous nivolumab approved in EU, Canada for solid tumors
      May 28th 2025

      Subcutaneous nivolumab approved in EU, Canada for solid tumors

      Hannah Clarke
      The approvals are supported by findings from the phase 3 CheckMate-67T trial.
      female doctor talking with male patient
      December 22nd 2022

      Dr. Katherine Rotker on destigmatizing sexual health

      Urology Times staff
      "I think there's a lot of fear that can go into talking about these topics," says Katherine Rotker, MD.
      Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
      May 15th 2025

      Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

      Tracey L. Krupski, MD Jeunice Owens-Walton, MD
      "The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
      Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC
      April 3rd 2025

      Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC

      Mehmet Asim Bilen, MD Hannah Clarke
      "The combination demonstrated clinical activity and an acceptable safety profile in the perioperative setting for locally advanced, non-metastatic clear cell RCC," says Mehmet Asim Bilen, MD.
      Close-up shot of microscope with metal lens at laboratory. | Image Credit: © kkolosov - stock.adobe.com
      April 2nd 2025

      The importance of federal funding in cancer research: A call to action

      Michael S. Cookson, MD, MMHC, FACS
      "We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS.
      FDA updates in urology: March 2025
      April 1st 2025

      FDA updates in urology: March 2025

      Hannah Clarke
      A recap of the FDA submissions and regulatory decisions in urology from March 2025.
      © 2025 MJH Life Sciences

      All rights reserved.